News articles about Celgene (NASDAQ:CELG) have been trending somewhat positive recently, Accern reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Celgene earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.3633043611824 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- CELGENE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC … (globenewswire.com)
- CELGENE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Celgene Corporation – CELG (finance.yahoo.com)
- Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Celgene Corporation (CELG) and Encourages Investors to Contact the Firm (markets.financialcontent.com)
- Cantor Fitzgerald Reiterates “$112.00” Price Target for Celgene (CELG) (americanbankingnews.com)
- Celgene (CELG) Given a $166.00 Price Target by Oppenheimer Analysts (americanbankingnews.com)
CELG has been the subject of a number of research reports. Credit Suisse Group set a $128.00 price objective on shares of Celgene and gave the company a “buy” rating in a research note on Tuesday, December 12th. Vetr cut shares of Celgene from a “strong-buy” rating to a “buy” rating and set a $121.72 price objective for the company. in a research note on Tuesday, December 12th. Oppenheimer set a $166.00 price objective on shares of Celgene and gave the company a “buy” rating in a research note on Thursday, December 14th. Leerink Swann reaffirmed a “buy” rating and issued a $120.00 price objective on shares of Celgene in a research note on Wednesday, December 13th. Finally, Stifel Nicolaus cut their price objective on shares of Celgene from $149.00 to $130.00 and set a “buy” rating for the company in a research note on Friday, December 22nd. Three research analysts have rated the stock with a sell rating, twelve have given a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $127.68.
Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, January 25th. The biopharmaceutical company reported $1.87 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.78 by $0.09. Celgene had a net margin of 22.38% and a return on equity of 67.50%. The business had revenue of $3.48 billion during the quarter, compared to analyst estimates of $3.46 billion. During the same period in the prior year, the business earned $1.61 EPS. The company’s revenue for the quarter was up 16.9% on a year-over-year basis. equities research analysts expect that Celgene will post 7.66 EPS for the current year.
Celgene declared that its Board of Directors has approved a stock buyback program on Wednesday, February 14th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s management believes its shares are undervalued.
In other Celgene news, insider Mark J. Alles purchased 3,260 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The stock was bought at an average cost of $91.90 per share, for a total transaction of $299,594.00. Following the purchase, the insider now directly owns 178,904 shares in the company, valued at $16,441,277.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $95.99, for a total transaction of $887,907.50. Following the completion of the transaction, the director now owns 94,801 shares of the company’s stock, valued at $9,099,947.99. The disclosure for this sale can be found here. Insiders sold a total of 41,120 shares of company stock valued at $3,879,509 over the last 90 days. Company insiders own 0.95% of the company’s stock.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.